Nova Patents
NO20004412L

Hiv peptides from tat,rev and wef conserved regions and their application as e.gvacine compnents

Abstract

The invention relates to: - novel and modified peptides which are based on HIV-regulating Tat and Rev proteins and Nef complementary proteins that are useful for the HIV-1 specific immune response without antagonizing effect on cytotoxic T-cell activity, peptide-containing antigens, - vaccines comprising azantigens, - a method for detecting HIV or HIV-specific peptides or proteins-induced antibody test fluid samples. The invention is applicable to HIV diagnostics and HIV therapeutic purposes. HE

Term

No projected expiry on record.

  1. Priority and filed
  2. Published
  3. Today

30 members in 18 offices

This recordMember, by publication datePriority claim8 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
20004412NorwayA
NO20000004412–––

Members30

Family members, oldest first
DocumentOfficeKind
NO20004412D0NorwayD0
NO20004412LThis recordNorwayL
CA2421199A1CanadaA1
WO0220555A2World Intellectual Property Organization (WIPO)A2
AU8633601AAustraliaA
WO0220555A3World Intellectual Property Organization (WIPO)A3
NO314587B1NorwayB1
EP1322666A2European Patent Office (EPO)A2
BR0114046ABrazilA
EA200300335A1Eurasian Patent Organization (EAPO)A1
SK4012003A3SlovakiaA3
CN1458936AChinaA
AR033997A1ArgentinaA1
JP2004508382AJapanA
ZA200301742BSouth AfricaB
US2005053616A1United States of AmericaA1
HU0303132A2HungaryA2
NZ524557ANew ZealandA
EA006210B1Eurasian Patent Organization (EAPO)B1
NZ535908ANew ZealandA
US7097971B2United States of AmericaB2
AU2001286336B2AustraliaB2
EP1322666B1European Patent Office (EPO)B1
AT378350TAustriaT
DE60131432D1GermanyD1
ES2296793T3SpainT3
DE60131432T2GermanyT2
CN101628933AChinaA
SK287913B6SlovakiaB6
HU0303132A3HungaryA3